[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1308
66. Aukerman DF, Aukerman MM, Browning D: Medical coverage of high school athletics in North Carolina. South Med J; 2006 Feb;99(2):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this cross-sectional study was to assess the quality and extent of medical coverage at high school athletic events in North Carolina.
  • METHODS: A questionnaire, mailed to all athletic directors at public and private North Carolina high school members of the North Carolina High School Athletic Association, was used to assess medical coverage.
  • RESULTS: Only 56% of the schools had coverage by either nationally or state certified athletic trainers.
  • Although 71% of schools had physician coverage at some athletic events, less than 10% of physician coverage included monitoring of athletic practices.
  • Only 27% of the schools surveyed felt that their existing medical coverage of athletic events could be considered adequate.
  • [MeSH-major] Athletic Injuries. Emergency Medical Services. Health Services Needs and Demand / statistics & numerical data. School Health Services / statistics & numerical data


67. Fontana GA: Downregulation of cough by exercise and voluntary hyperpnea. Lung; 2010 Jan;188 Suppl 1:S95-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intensity of the urge-to-cough (UTC), a cognitive component of coughing, was also recorded throughout the trials.
  • The log-log relationship between inhaled fog concentrations and the correspondingly evoked UTC values, an index of the perceptual magnitude of the UTC sensitivity, was also calculated.
  • With exercise and VIH compared with control, mean UTC values at cough threshold were not significantly changed: control, 3.83 +/- 1.11 cm; exercise, 3.12 +/- 0.82 cm; VIH, 4.08 +/- 1.67 cm.
  • Since the slopes of the log fog concentration/log UTC value were approximately halved during exercise and VIH compared with control, the UTC sensitivity to fog was depressed (p < 0.01).


68. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M: Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res; 2007 Feb 15;13(4):1161-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
  • PURPOSE: To investigate the overall occurrence and relationship of genetic alterations in the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in thyroid tumors and explore the scope of this pathway as a therapeutic target for thyroid cancer.
  • EXPERIMENTAL DESIGN: We examined collectively the major genetic alterations and their relationship in this pathway, including PIK3CA copy number gain and mutation, Ras mutation, and PTEN mutation, in a large series of primary thyroid tumors.
  • RESULTS: Occurrence of any of these genetic alterations was found in 25 of 81 (31%) benign thyroid adenoma (BTA), 47 of 86 (55%) follicular thyroid cancer (FTC), 21 of 86 (24%) papillary thyroid cancer (PTC), and 29 of 50 (58%) anaplastic thyroid cancer (ATC), with FTC and ATC most frequently harboring these genetic alterations.
  • A mutual exclusivity among these genetic alterations was seen in BTA, FTC, and PTC, suggesting an independent role of each of them through the PI3K/Akt pathway in the tumorigenesis of the differentiated thyroid tumors.
  • However, coexistence of these genetic alterations was increasingly seen with progression from differentiated tumor to undifferentiated ATC.
  • Their coexistence with BRAF mutation was also frequent in PTC and ATC.
  • CONCLUSIONS: The data provide strong genetic implication that aberrant activation of PI3K/Akt pathway plays an extensive role in thyroid tumorigenesis, particularly in FTC and ATC, and promotes progression of BTA to FTC and to ATC as the genetic alterations of this pathway accumulate.
  • Progression of PTC to ATC may be facilitated by coexistence of PI3K/Akt pathway-related genetic alterations and BRAF mutation.
  • The PI3K/Akt pathway may thus be a major therapeutic target in thyroid cancers.
  • [MeSH-major] Oncogene Protein v-akt / genetics. Phosphatidylinositol 3-Kinases / genetics. Thyroid Neoplasms / enzymology. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317825.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R0-1 CA113507-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / Oncogene Protein v-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


69. Mulder H, Heerdink ER, van Iersel EE, Wilmink FW, Egberts AC: Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Ann Pharmacother; 2007 Mar;41(3):408-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In total, 416 drugs metabolized by CYP2D6 were prescribed, with 257 (62%) of these classified as an antidepressant (Anatomical and Therapeutic Chemical [ATC] category N06A) or antipsychotic (ATC N05A).

  • MedlinePlus Health Information. consumer health - Antidepressants.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341534.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antipsychotic Agents; EC 1.14.14.1 / Cytochrome P-450 CYP2D6
  •  go-up   go-down


70. Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi AR, Tavangar SM, Malekzadeh R, Larijani B: Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer; 2006 Apr-Jun;43(2):80-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine cancer in Iran: based on cancer registry system.
  • BACKGROUND: A population-based registry of endocrine cancer cases in four Iranian provinces, was performed for the years 1996-2000.
  • MATERIALS AND METHODS: Patients in each province were grouped according to age, gender and tumor specifics (site, morphology, behavior) and the data was coded according to the international classification of diseases for oncology.
  • RESULTS: A total of 319 cases of primary endocrine cancer were found and registered, including 313 cases of thyroid carcinoma and 6 cases of adrenal cancer.
  • The thyroid carcinoma group cases consisted of papillary (82.7%), follicular (8.6%), medullary (7.0%) and anaplastic (1.6%) carcinomas.
  • The ASR for thyroid carcinoma was 1.289 (0.627 for men, 1.59 for women), with the highest incidence rate in Kerman (ASR 1.643) and the lowest incidence rate in Golestan (ASR 0.735).
  • For the 6 cases of adrenal cancer, 4 were neuroblastoma and 2 were pheochromocytoma.
  • Considering the effect of improvement in the iodine intake in previously deficient communities, which is associated with an increase in the incidence of papillary carcinoma compared to other histologic types, the frequency and distribution of histologic types of thyroid carcinoma was closer to what can be seen in iodine-rich areas.
  • [MeSH-major] Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. Registries / statistics & numerical data
  • [MeSH-minor] Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / pathology. Adolescent. Adrenal Gland Neoplasms / epidemiology. Adrenal Gland Neoplasms / pathology. Adult. Age Distribution. Aged. Carcinoma, Medullary / epidemiology. Carcinoma, Medullary / pathology. Carcinoma, Papillary. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Iodine / metabolism. Iran / epidemiology. Male. Middle Aged. Pheochromocytoma / epidemiology. Pheochromocytoma / pathology. Retrospective Studies. Sex Distribution. Thyroid Neoplasms / epidemiology. Thyroid Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790945.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 9679TC07X4 / Iodine
  •  go-up   go-down


71. Weidner TG, Henning JM: Importance and applicability of approved clinical instructor standards and criteria to certified athletic trainers in different clinical education settings. J Athl Train; 2005 Oct-Dec;40(4):326-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance and applicability of approved clinical instructor standards and criteria to certified athletic trainers in different clinical education settings.
  • CONTEXT: For optimal clinical education of athletic training students, Clinical Instructor Educators and program directors need to proactively select, train, and evaluate their Approved Clinical Instructors (ACIs).
  • OBJECTIVE: To assess the relative importance and applicability of ACI standards to certified athletic trainers employed in different athletic training clinical education settings.
  • CONCLUSIONS: The Weidner and Henning standards are considered to be important and applicable across a variety of athletic training clinical education settings.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404455.001).
  • [ISSN] 1062-6050
  • [Journal-full-title] Journal of athletic training
  • [ISO-abbreviation] J Athl Train
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1323295
  •  go-up   go-down


72. Haberthür C, Guttmann J: Short-term effects of positive end-expiratory pressure on breathing pattern: an interventional study in adult intensive care patients. Crit Care; 2005 Aug;9(4):R407-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In 30 tracheally intubated, spontaneously breathing patients, we sequentially applied PEEP to the trachea at 0, 5 and 10 cmH2O, and then again at 5 cmH2O for 30 s each, using the automatic tube compensation mode.
  • Post hoc analysis revealed a similar but stronger response in patients with impaired respiratory system compliance.

  • MedlinePlus Health Information. consumer health - Critical Care.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2000 Nov;162(5):1633-40 [11069788.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Sep;160(3):950-60 [10471624.001]
  • [Cites] J Appl Physiol (1985). 2001 Jun;90(6):2330-40 [11356800.001]
  • [Cites] Crit Care Med. 2003 Nov;31(11):2619-26 [14605533.001]
  • [Cites] Technol Health Care. 2003;11(6):413-24 [14757920.001]
  • [Cites] Br Med J. 1974 Jun 22;2(5920):656-9 [4835444.001]
  • [Cites] J Appl Physiol. 1975 May;38(5):869-74 [1126897.001]
  • [Cites] J Appl Physiol. 1975 Mar;38(3):474-80 [168175.001]
  • [Cites] J Pediatr. 1977 Jun;90(6):976-81 [323448.001]
  • [Cites] Respir Physiol. 1981 Sep;45(3):343-55 [6800008.001]
  • [Cites] Am J Physiol. 1986 May;250(5 Pt 2):R902-9 [3706575.001]
  • [Cites] Respir Physiol. 1988 Aug;73(2):145-54 [3420318.001]
  • [Cites] J Appl Physiol (1985). 1990 Mar;68(3):1092-100 [2140347.001]
  • [Cites] J Appl Physiol (1985). 1991 Aug;71(2):474-80 [1938718.001]
  • [Cites] Pediatr Pulmonol. 1991;11(4):345-9 [1758760.001]
  • [Cites] J Appl Physiol (1985). 1992 Mar;72(3):881-7 [1533214.001]
  • [Cites] J Appl Physiol (1985). 1992 Aug;73(2):479-85 [1399969.001]
  • [Cites] Anesthesiology. 1993 Sep;79(3):503-13 [8363076.001]
  • [Cites] Respir Physiol. 1993 Aug;93(2):175-87 [8210757.001]
  • [Cites] Respir Med. 1996 Sep;90(8):463-6 [8869439.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):938-44 [8887589.001]
  • [Cites] J Appl Physiol (1985). 1998 Dec;85(6):2033-9 [9843523.001]
  • [Cites] Intensive Care Med. 1999 May;25(5):514-9 [10401948.001]
  • [Cites] Respiration. 2001;68(2):140-4 [11287827.001]
  • (PMID = 16137354.001).
  • [ISSN] 1466-609X
  • [Journal-full-title] Critical care (London, England)
  • [ISO-abbreviation] Crit Care
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  • [Other-IDs] NLM/ PMC1269457
  •  go-up   go-down


73. Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, Iaccarino A, Russo M, Pierantoni GM, Leone V, Sacchetti S, Troncone G, Santoro M, Fusco A: Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res; 2008 Aug 15;68(16):6770-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer.
  • Using gene expression profiling, we found that the CBX7 gene was drastically down-regulated in six thyroid carcinoma cell lines versus control cells.
  • The aims of this study were to determine whether CBX7 is related to the thyroid cancer phenotype and to try to identify new tools for the diagnosis and prognosis of thyroid cancer.
  • We thus evaluated CBX7 expression in various snap-frozen and paraffin-embedded thyroid carcinoma tissues of different degrees of malignancy by quantitative reverse transcription-PCR and immunohistochemistry, respectively.
  • Indeed, it decreased in an increasing percentage of cases going from benign adenomas to papillary (PTC), follicular, and anaplastic (ATC) thyroid carcinomas.
  • This finding coincides with results obtained in rat and mouse models of thyroid carcinogenesis.
  • CBX7 loss of heterozygosity occurred in 36.8% of PTC and in 68.7% of ATC.
  • Restoration of CBX7 expression in thyroid cancer cells reduced growth rate, with a retention in the G(1) phase of the cell cycle, suggesting that CBX7 can contribute to the proliferation of the transformed thyroid cells.
  • In conclusion, loss of CBX7 expression correlates with a highly malignant phenotype in thyroid cancer patients.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma / genetics. Carcinoma, Papillary / genetics. Repressor Proteins / genetics. Repressor Proteins / metabolism. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenoviridae / genetics. Animals. Blotting, Western. Cell Line, Tumor. Cell Proliferation. Chromosomes, Human, Pair 22 / genetics. Colony-Forming Units Assay. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Gene Expression Regulation, Neoplastic. Humans. Loss of Heterozygosity. Mice. Mice, Nude. Polycomb Repressive Complex 1. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Rats. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701502.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBX7 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


7
Advertisement
4. Zhang C, Huang Y: Complete mitochondrial genome of Oxya chinensis (Orthoptera, Acridoidea). Acta Biochim Biophys Sin (Shanghai); 2008 Jan;40(1):7-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The initiation codon of the cytochrome oxidase subunit I gene in the mitochondrial genome of O. chinensis appears to be ATC, instead of the tetranucleotides that have been reported in Locusta migratoria (L. migratoria) mitochondrial genome.
  • [MeSH-major] DNA, Mitochondrial / genetics. Genome / genetics. Mitochondria / genetics. Orthoptera / classification. Orthoptera / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180849.001).
  • [ISSN] 1745-7270
  • [Journal-full-title] Acta biochimica et biophysica Sinica
  • [ISO-abbreviation] Acta Biochim. Biophys. Sin. (Shanghai)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


75. Woyach JA, Shah MH: New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer; 2009 Sep;16(3):715-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New therapeutic advances in the management of progressive thyroid cancer.
  • The spectrum of thyroid cancers ranges from one of the most indolent to one of the most aggressive solid tumors identified.
  • Conventional therapies for thyroid cancers are based on the histologic type of thyroid cancers such as papillary or follicular thyroid cancer (differentiated thyroid cancer (DTC)), medullary thyroid cancer (MTC), or anaplastic thyroid cancer (ATC).
  • While surgery is one of the key treatments for all such types of thyroid cancers, additional therapies vary.
  • Effective targeted therapy for DTC is a decades-old practice with systemic therapies of thyroid stimulating hormone suppression and radioactive iodine therapy.
  • However, for the iodine-refractory DTC, MTC, and ATC there is no effective systemic standard of care treatment.
  • Recent advances in understanding pathogenesis of DTC and development of molecular targeted therapy have dramatically transformed the field of clinical research in thyroid cancer.
  • Over the last five years, incredible progress has been made and phases I-III clinical trials have been conducted in various types of thyroid cancers with some remarkable results that has made an impact on lives of patients with thyroid cancer.
  • Such history-making events have boosted enthusiasm and interest among researchers, clinicians, patients, and sponsors and we anticipate ongoing efforts to develop more effective and safe therapies for thyroid cancer.
  • [MeSH-major] Antineoplastic Protocols. Carcinoma / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Animals. Carcinoma, Medullary / etiology. Carcinoma, Medullary / therapy. Carcinoma, Papillary / etiology. Carcinoma, Papillary / therapy. Clinical Trials as Topic / methods. Clinical Trials as Topic / trends. Disease Progression. Drug Evaluation, Preclinical / methods. Drug Evaluation, Preclinical / trends. Humans. Models, Biological

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218279.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 106
  •  go-up   go-down


76. Pohjanoksa-Mäntylä MK, Antila J, Eerikäinen S, Enäkoski M, Hannuksela O, Pietilä K, Airaksinen M: Utilization of a community pharmacy-operated national drug information call center in Finland. Res Social Adm Pharm; 2008 Jun;4(2):144-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority (83%) of these calls were therapeutic or pharmaceutical inquiries, with 26% concerning costs and reimbursements, 14% interactions, 14% dosages, and 11% adverse effects.
  • Nervous system drugs (Anatomical Therapeutic Chemical [ATC] classification N), anti-infectives (J), and musculoskeletal drugs (M) accounted for 20%, 18%, and 13% of the calls, respectively.
  • Nonsteroidal anti-inflammatory drugs (NSAID) (9% of the calls), antidepressants (6%), and penicillin (5%) were the most often inquired about ATC-subgroups.
  • This may especially be the case for certain population groups, and in regard to nervous system drugs, anti-infectives and NSAID.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555967.001).
  • [ISSN] 1551-7411
  • [Journal-full-title] Research in social & administrative pharmacy : RSAP
  • [ISO-abbreviation] Res Social Adm Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Perrier E, Manen O, Cinquetti G: Essential thrombocytosis and myocardial infarction in an aircrew member: aeromedical concerns. Aviat Space Environ Med; 2006 Jan;77(1):69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the case of a 40-yr-old, female French military air traffic controller (ATC) admitted for an ST-elevation myocardial infarction.
  • The diagnosis of ET was then established.
  • No platelet-lowering therapy was prescribed, aspirin was continued, and this ATC was considered unfit for operational duties.
  • [MeSH-major] Military Personnel. Myocardial Infarction / etiology. Thrombocytosis / diagnosis. Work Capacity Evaluation
  • [MeSH-minor] Adult. Aerospace Medicine. Aspirin / therapeutic use. Coronary Angiography. Coronary Thrombosis / radiography. Coronary Thrombosis / therapy. Female. Humans. Platelet Aggregation Inhibitors / therapeutic use. Smoking

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422458.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin
  •  go-up   go-down


78. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, Nakamura N, Yamane T, Kobayashi M, Katoh R: Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest; 2009 Jul;89(7):791-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas.
  • Thyroid transcription factor-1 (TTF-1), also known as NKX2-1, is a homeodomain containing transcriptional factor identified in thyroid, lung and central nervous system.
  • In the thyroid, TTF-1 is essential for thyroid organogenesis and governs thyroid functions by regulating various thyroid-specific genes.
  • We previously demonstrated that most differentiated thyroid neoplasms, including follicular adenomas/carcinomas and papillary carcinomas, express TTF-1 at both protein and mRNA levels.
  • However, certain subtypes of thyroid cancers have shown low or negative expression of TTF-1.
  • The aim of our study was to investigate the function of epigenetic modification in dysregulation of TTF-1 in thyroid carcinoma cells.
  • We evaluated the expression of TTF-1 in primary thyroid tissues (normal thyroid, papillary carcinoma and undifferentiated carcinoma) and in thyroid carcinoma cell lines using immunohistochemistry and RT-PCR.
  • We also explored whether epigenetic modifiers, including 5-aza-deoxycytidine, could restore TTF-1 expression in thyroid carcinoma cells.
  • In our current study, immunohistochemistry and RT-PCR showed positive expression of TTF-1 in normal thyroids and papillary carcinomas.
  • Meanwhile, most of the undifferentiated carcinomas and the cell lines lost TTF-1 expression.
  • No methylation in the CpG of TTF-1 promoter was detected in normal thyroids or papillary carcinomas.
  • In contrast, DNA methylation was identified in 60% of the undifferentiated carcinomas (6/10) and 50% of the cell lines (4/8).
  • ChIP assay demonstrated that acetylation of H3-lys9 was positively correlated with TTF-1 expression in thyroid carcinoma cells.
  • Finally, DNA demethylating agents could restore TTF-1 gene expression in the thyroid carcinoma cell lines.
  • Our data suggest that epigenetics is involved with inactivation of TTF-1 in thyroid carcinomas, and provide a possible means of using TTF-1 as a target for differentiation-inducing therapy through epigenetic modification.
  • [MeSH-major] DNA Methylation. Gene Silencing. Histones / metabolism. Nuclear Proteins / genetics. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism. Transcription Factors / genetics
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Base Sequence. Carcinoma, Papillary / etiology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Cell Line, Tumor. Chromatin Immunoprecipitation. CpG Islands. DNA Primers / genetics. Epigenesis, Genetic / drug effects. Gene Expression Profiling. Humans. Hydroxamic Acids / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Thyroid Gland / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506552.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Histones; 0 / Hydroxamic Acids; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


79. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N: Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res; 2009 Dec 1;15(23):7153-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We compared the response of MM cells versus several epithelial cancer models to the proteasome inhibitor bortezomib in combination with nutlin-3.
  • Importantly, however, in breast, prostate, colon, and thyroid (papillary, follicular, anaplastic, and medullary) carcinoma cell lines, this combination triggered synergistic cytotoxicity, and increased expression of p53, p21, Hdm2, Bax, Noxa, PUMA, and cleavage of caspase-3 and poly ADP ribose polymerase.
  • CONCLUSIONS: This differential response of MM versus epithelial carcinomas to combination of nutlin-3 with bortezomib sheds new light on the role of p53 in bortezomib-induced apoptosis.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Dec 1;165(11):6347-55 [11086072.001]
  • [Cites] Cell Death Differ. 2010 Jan;17(1):86-92 [19543236.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):673-82 [11463391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1530-4 [12393500.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5556-71 [12897130.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Genes Dev. 1993 Jul;7(7A):1126-32 [8319905.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1646-56 [9880544.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):439-44 [15542427.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1461-6 [15608685.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3609-17 [16081689.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1092-100 [16234364.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] Blood. 2006 Aug 1;108(3):993-1000 [16543464.001]
  • [Cites] Curr Drug Targets. 2006 Oct;7(10):1341-7 [17073596.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3177-88 [17185464.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):950-68 [17546631.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3892-901 [17679727.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3071-6 [11306489.001]
  • (PMID = 19934289.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA050947-17A1; United States / NCI NIH HHS / CA / R01 CA050947; United States / NCI NIH HHS / CA / R01 CA050947-17A1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Imidazoles; 0 / Piperazines; 0 / Proteasome Inhibitors; 0 / Pyrazines; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ NIHMS145802; NLM/ PMC3672410
  •  go-up   go-down


80. Kopjar N, Zeljezić D, Kasuba V, Rozgaj R: [Antineoplastic drugs as a potential risk factor in occupational settings: mechanisms of action at the cell level, genotoxic effects, and their detection using different biomarkers]. Arh Hig Rada Toksikol; 2010 Mar;61(1):121-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Classification of antineoplastic drugs according to the IARC monographs on the evaluation of carcinogenic risks to humans is accompanied by data on their mutagenicity and the most recent updates in the Anatomical Therapeutic Chemical (ATC) Classification System.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20338875.001).
  • [ISSN] 0004-1254
  • [Journal-full-title] Arhiv za higijenu rada i toksikologiju
  • [ISO-abbreviation] Arh Hig Rada Toksikol
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 212
  •  go-up   go-down


81. Lin D, Ippolito GC, Zong RT, Bryant J, Koslovsky J, Tucker P: Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer. Mol Cancer; 2007 Mar 26;6:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bright positively activates IgH transcriptional initiation by binding to ATC-rich P sites within nuclear matrix attachment regions (MARs) flanking the IgH intronic enhancer (Emu).
  • A system was established in which VH promoter-driven in vitro transcription on chromatin- reconstituted templates was responsive to Emu.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):5206-11 [1922040.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):5197-205 [1922039.001]
  • [Cites] Science. 1993 Jul 2;261(5117):82-6 [8316859.001]
  • [Cites] Genes Dev. 1993 Oct;7(10):2016-32 [8406005.001]
  • [Cites] Science. 1994 Aug 26;265(5176):1221-5 [8066460.001]
  • [Cites] J Immunol. 1995 Nov 1;155(9):4270-7 [7594585.001]
  • [Cites] Genes Dev. 1995 Dec 15;9(24):3067-82 [8543152.001]
  • [Cites] J Biol Chem. 1996 Oct 4;271(40):25041-8 [8798787.001]
  • [Cites] EMBO J. 1996 Sep 16;15(18):5014-21 [8890174.001]
  • [Cites] Nature. 1997 Jan 16;385(6613):269-72 [9000077.001]
  • [Cites] Mol Cell Biol. 1997 May;17(5):2658-68 [9111336.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3527-35 [9199288.001]
  • [Cites] J Immunol. 1998 May 15;160(10):4747-54 [9590220.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3596-603 [9584200.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5121-7 [9710596.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4858-62 [9988726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1526-31 [9990057.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15633-45 [10336460.001]
  • [Cites] Methods Enzymol. 1999;304:399-414 [10372373.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1998;63:515-24 [10384316.001]
  • [Cites] Immunity. 1999 Jul;11(1):11-20 [10435575.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3741-7 [10446990.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6632-41 [10490602.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2834-42 [15728493.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2073-84 [15743806.001]
  • [Cites] Genomics. 2005 Aug;86(2):242-51 [15922553.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14362-7 [16186486.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2187-201 [16507996.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4758-68 [16738337.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1573-7 [8079170.001]
  • [Cites] Genes Dev. 1994 Oct 15;8(20):2453-65 [7958909.001]
  • [Cites] Mol Cell Biol. 1995 Jun;15(6):3217-26 [7760817.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):3003-14 [10580007.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1999;9(3-4):295-310 [10651246.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):4123-33 [10921892.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):196-208 [11113195.001]
  • [Cites] Trends Biochem Sci. 2001 Jan;26(1):7-9 [11165500.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:99-107 [11232342.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:109-18 [11232275.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(8):2918-32 [11283269.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21325-30 [11294836.001]
  • [Cites] EMBO J. 2001 Nov 15;20(22):6394-403 [11707410.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):148-53 [11812999.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2477-87 [12193717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15030-5 [12415115.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11577-82 [14500909.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42106-14 [12907668.001]
  • [Cites] Mol Immunol. 2004 Jan;40(10):723-31 [14644098.001]
  • [Cites] J Biomol NMR. 2004 Apr;28(4):357-67 [14872127.001]
  • [Cites] Immunol Rev. 2004 Aug;200:182-96 [15242405.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 May;79(9):2996-3000 [6806821.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] Nature. 1986 Oct 9-15;323(6088):548-51 [3093895.001]
  • [Cites] J Biol Chem. 1987 Apr 15;262(11):5394-7 [3031052.001]
  • [Cites] Mol Cell Biol. 1987 Jul;7(7):2558-67 [3039350.001]
  • [Cites] Genes Dev. 1988 Oct;2(10):1227-37 [3264542.001]
  • [Cites] Genes Dev. 1989 Aug;3(8):1255-66 [2792763.001]
  • [Cites] Mol Cell Biol. 1990 Mar;10(3):982-90 [2304473.001]
  • [Cites] Nucleic Acids Res. 1990 May 11;18(9):2643-8 [2111008.001]
  • [Cites] EMBO J. 1993 Jun;12(6):2321-7 [8508765.001]
  • (PMID = 17386101.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA110624; United States / NCI NIH HHS / CA / R01 CA031534; United States / NCI NIH HHS / CA / 1F32CA110624-01A1; United States / NCI NIH HHS / CA / CA31534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARID3A protein, human; 0 / Chromatin; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Heavy Chains; 0 / Trans-Activators; 0 / Transcription Factors; EC 3.1.- / Deoxyribonucleases
  • [Other-IDs] NLM/ PMC1852116
  •  go-up   go-down


82. Zhu XG, Cheng SY: Modeling thyroid cancer in the mouse. Horm Metab Res; 2009 Jun;41(6):488-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling thyroid cancer in the mouse.
  • Thyroid carcinomas, the most common endocrine tumors in humans, have an increasing incidence in the U.S. and worldwide.
  • There are four major types of thyroid cancers: papillary, follicular, anaplastic, and medullary carcinomas.
  • In recent years, significant progress has been made in the identification of genetic alterations in thyroid carcinomas, particularly, papillary and medullary thyroid cancers.
  • Mouse models of thyroid cancer are valuable tools in elucidating molecular genetic changes underlying thyroid carcinogenesis and in identifying potential molecular targets for therapeutic intervention.
  • Representative mouse models of papillary, follicular, and medullary carcinomas are reviewed here with particular emphasis on those for follicular thyroid carcinomas.
  • Challenges for further development in the modeling of thyroid cancer will also be discussed.
  • [MeSH-major] Carcinoma / pathology. Disease Models, Animal. Mice. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2002 Winter;13(4):271-88 [12665646.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Dev Dyn. 2003 Jul;227(3):367-78 [12815622.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4777-80 [12941793.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(18):6542-52 [12944480.001]
  • [Cites] Trends Endocrinol Metab. 2003 Sep;14(7):327-33 [12946875.001]
  • [Cites] Carcinogenesis. 2003 Sep;24(9):1467-79 [12869418.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 [12970322.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5274-80 [14500358.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):58-62 [14736524.001]
  • [Cites] Mol Cell Endocrinol. 2003 Dec 31;213(1):31-45 [15062572.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4430-8 [15231697.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):263-74 [15380517.001]
  • [Cites] Endocr Rev. 2004 Oct;25(5):722-46 [15466939.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] Acta Biomed. 2004 Aug;75(2):114-7 [15481700.001]
  • [Cites] Adv Exp Med Biol. 1986;206:529-42 [3591538.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(16):5923-7 [3112776.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] Oncogene. 1990 Apr;5(4):565-70 [2183158.001]
  • [Cites] Mol Endocrinol. 1990 Oct;4(10):1474-9 [2283998.001]
  • [Cites] Endocrinology. 1991 Sep;129(3):1391-401 [1714832.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Nov;73(5):990-4 [1682340.001]
  • [Cites] J Clin Invest. 1991 Dec;88(6):2123-30 [1661299.001]
  • [Cites] EMBO J. 1992 Feb;11(2):537-42 [1371462.001]
  • [Cites] Development. 1991 Dec;113(4):1093-104 [1811929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6232-6 [1631115.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5523-7 [8221693.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2979-85 [8187085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10488-92 [7937980.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1146-51 [7867001.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1789-97 [7753555.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):376-85 [7795643.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):375-8 [8536638.001]
  • [Cites] Oncogene. 1995 Dec 21;11(12):2459-67 [8545102.001]
  • [Cites] Oncogene. 1996 Jan 4;12(1):111-8 [8552381.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1821-6 [8622903.001]
  • [Cites] J Clin Endocrinol Metab. 1996 May;81(5):2006-9 [8626874.001]
  • [Cites] Oncogene. 1996 Oct 3;13(7):1471-82 [8875985.001]
  • [Cites] Endocrinology. 1997 Jan;138(1):369-78 [8977426.001]
  • [Cites] Toxicol Pathol. 1997 Jan-Feb;25(1):39-48 [9061850.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):307-18 [9121114.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3330-5 [9096393.001]
  • [Cites] Horm Res. 1997;47(4-6):137-9 [9167944.001]
  • [Cites] Endocrinology. 1997 Aug;138(8):3133-40 [9231760.001]
  • [Cites] Oncogene. 1998 Jan 15;16(2):167-77 [9464534.001]
  • [Cites] Oncogene. 1998 Sep 24;17(12):1625-8 [9794240.001]
  • [Cites] Biol Cell. 1998 Sep;90(5):369-80 [9835011.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5523-8 [9850089.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] Langenbecks Arch Surg. 1999 Feb;384(1):16-23 [10367625.001]
  • [Cites] Oncogene. 1999 Jun 17;18(24):3659-65 [10380889.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Apr;50(4):529-35 [10468914.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):46868-75 [15331589.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):319-27 [15681856.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):122-9 [15719378.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4238-45 [15899815.001]
  • [Cites] J Natl Cancer Inst. 2005 May 18;97(10):703-5 [15900034.001]
  • [Cites] J Natl Cancer Inst. 2005 May 18;97(10):724-32 [15900042.001]
  • [Cites] Am J Epidemiol. 2005 Jun 1;161(11):1056-65 [15901626.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2261-8 [15880523.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):245-62 [15947100.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Sep;161(2):104-9 [16102579.001]
  • [Cites] Endocrinology. 2005 Oct;146(10):4456-63 [16002527.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Nov;5(6):927-46 [16255634.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1780-5 [16446424.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2736-47 [16314832.001]
  • [Cites] Oncogene. 2006 Aug 31;25(39):5467-74 [16785999.001]
  • [Cites] J Clin Invest. 2006 Nov;116(11):2972-84 [17039256.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):936-41 [16946010.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):1306-12 [17170101.001]
  • [Cites] Steroids. 2007 Feb;72(2):171-9 [17169389.001]
  • [Cites] Carcinogenesis. 2007 May;28(5):932-9 [17127711.001]
  • [Cites] Mol Cell Biol. 2007 Sep;27(17):6116-26 [17606624.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):957-77 [18045949.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2451-8 [17660507.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Jan;8(1):83-95 [18088233.001]
  • [Cites] Oncogene. 2008 Jan 31;27(6):823-30 [17653082.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):625-32 [18402529.001]
  • [Cites] Horm Metab Res. 2008 May;40(5):323-8 [18491251.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):363-74, viii [18502331.001]
  • [Cites] Mol Cell Biol. 2008 Jul;28(14):4598-608 [18474620.001]
  • [Cites] Endocrinology. 2008 Oct;149(10):5107-17 [18583418.001]
  • [Cites] Br J Cancer. 2008 Dec 2;99(11):1874-83 [18985036.001]
  • [Cites] Cancer Invest. 2008 Nov;26(9):948-55 [18798058.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1053-60 [12651598.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):991-7 [10566554.001]
  • [Cites] Pathol Res Pract. 2000;196(1):1-7 [10674266.001]
  • [Cites] Thyroid. 2000 Jan;10(1):19-23 [10691309.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):671-7 [10934169.001]
  • [Cites] Oncogene. 2000 Aug 10;19(34):3948-54 [10951588.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Science. 2000 Oct 6;290(5489):138-41 [11021799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13209-14 [11069286.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5729-35 [11126359.001]
  • [Cites] Toxicol Pathol. 2001 Jan-Feb;29(1):8-33 [11215688.001]
  • [Cites] EMBO Rep. 2000 Aug;1(2):127-32 [11265751.001]
  • [Cites] EMBO Rep. 2000 Aug;1(2):133-9 [11265752.001]
  • [Cites] Eur J Surg Oncol. 2001 Mar;27(2):157-61 [11289751.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):3-16 [12114746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15462-7 [12432093.001]
  • [Cites] Thyroid. 2002 Nov;12(11):963-9 [12490073.001]
  • (PMID = 19358084.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA BC011191-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Germany
  • [Number-of-references] 111
  • [Other-IDs] NLM/ NIHMS405500; NLM/ PMC3464089
  •  go-up   go-down


83. Sinorita H, Madiyan M, Pramono RB, Purnama LB, Ikhsan MR, Asdie AH: ACE gene insertion/deletion polymorphism among patients with type 2 diabetes, and its relationship with metabolic syndrome at Sardjito Hospital Yogyakarta, Indonesia. Acta Med Indones; 2010 Jan;42(1):12-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the ACE genotype of the patients, a genomic DNA fragment on intron 16 of the ACE gene was amplified by polymerase chain reaction (PCR) using a forward primer 5'-CTG GAG ACC ACT CCC ATC CTT TCT-3' and reverse primer 5'-GAT GTG GCC ATC ACA RTC GTC AGA T-3'.


84. Cruciol-Souza JM, Thomson JC: Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci; 2006;9(3):427-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Potential DDI were identified using DrugReax system.
  • Patient's age and gender, number of prescribers; number of drugs and therapeutic drug classes on prescriptions were explored as associated factors to DDI.
  • The rate of potential DDI was significantly associated to in-patients' gender [woman, Odds ratio (OR)=1.23 (P=0.035)], age=55 years old [OR=1.5 (P=0.0008)], number of therapeutic drug class (ATC code, level 1)=4 [OR=5.5 (P=0.0000), cardiology patients [OR=7.87 (P=0.0000)] hospitalized at weekends [OR=1.24 (P=0.039)] and having digoxin prescribed [OR=16.79 (P=0.0000)].
  • A positive correlation was found between DDI, patient's age, number of drugs and therapeutic action ATC codes were significant, controlling for gender (Pearson's r=0.628, P=0.001).

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207423.001).
  • [ISSN] 1482-1826
  • [Journal-full-title] Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques
  • [ISO-abbreviation] J Pharm Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


85. Goldenberg D, Zagon IS, Fedok F, Crist HS, McLaughlin PJ: Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer. Thyroid; 2008 Nov;18(11):1165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer.
  • BACKGROUND: Although thyroid cancers are readily treatable with surgery and radioactive iodine, there are problems in managing recurring, as well as locally advanced, thyroid cancer.
  • In the present study we examined the presence and distribution of OGF and OGFr in nonmedullary thyroid cancer, including papillary, follicular, and anaplastic, as well as thyroid tissue from patients with nonmalignant disease.
  • METHODS: Patient samples of thyroid cancers and goiter were collected at the time of resection and processed for immunohistochemistry of OGF and OGFr, as well as pharmacological binding assays for OGFr.
  • RESULTS: Both peptide and receptor were detected in the cytoplasm and nucleus of all nonmedullary thyroid cancers, as well as in goiter.
  • Specific and saturable binding of OGFr was found in all thyroid samples.
  • CONCLUSIONS: The finding that a potent negative growth regulator and its receptor are present in nonmedullary thyroid cancers and thyroid tissues from patients with nonmalignant disease lead us to suggest that the OGF-OGFr axis serves as a regulator of cell proliferation in these tissues.
  • Moreover, modulation of this biological system may be used to treat progression of nonmedullary thyroid neoplasias.
  • [MeSH-major] Enkephalin, Methionine / metabolism. Receptors, Opioid / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adult. Aged. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Humans. Immunohistochemistry. Kinetics. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19014324.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Opioid; 0 / methionine-enkephalin receptor; 58569-55-4 / Enkephalin, Methionine
  •  go-up   go-down


86. Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E: Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf); 2006 Jan;64(1):105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
  • OBJECTIVES: The genes RET and RAS, and more recently BRAF, have been shown to be frequently mutated in human papillary thyroid carcinomas (PTC).
  • The aim of this study was to genotype for these mutations a cohort of thyroid tumours collected at our institutions.
  • DESIGN AND PATIENTS: Thyroid tumours removed from 51 subjects were analysed, including 43 PTC and 8 non-PTC tumours [3 follicular adenomas (FA), 4 follicular carcinomas (FTC) and 1 anaplastic carcinoma (AC)].
  • [MeSH-major] Carcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402937.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


87. de Oliveira Martins S, Soares MA, Foppe van Mil JW, Cabrita J: Inappropriate drug use by Portuguese elderly outpatients--effect of the Beers criteria update. Pharm World Sci; 2006 Oct;28(5):296-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The drugs were distributed mainly in the following 3 ATC (Anatomical Therapeutic Chemical Classification) classes: C (cardiovascular system), N (nervous system) and A (alimentary tract).
  • According to the ATC Classification, more than one half of the cases of inappropriateness were related with long acting benzodiazepines and with ticlopidine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Geriatr Soc. 2002 Jan;50(1):26-34 [12028243.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):127-34 [11998537.001]
  • [Cites] Ann Pharmacother. 2002 Mar;36(3):404-9 [11895051.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1825-32 [1888249.001]
  • [Cites] Pharmacotherapy. 2000 Feb;20(2):221-8 [10678301.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2716-24 [14662625.001]
  • [Cites] Age Ageing. 2000 Jan;29(1):35-9 [10690693.001]
  • [Cites] J Am Geriatr Soc. 2004 Nov;52(11):1934-9 [15507075.001]
  • [Cites] Int J Geriatr Psychiatry. 1999 Apr;14(4):280-4 [10340189.001]
  • [Cites] BMC Geriatr. 2004 Oct 15;4:9 [15488143.001]
  • [Cites] JAMA. 1998 Oct 14;280(14):1249-52 [9786375.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2004 Oct;13(10):669-82 [15386589.001]
  • [Cites] J Am Geriatr Soc. 1994 Dec;42(12):1241-7 [7983285.001]
  • [Cites] Arch Intern Med. 1997 Jul 28;157(14):1531-6 [9236554.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Dec;1(2):61-74 [15555468.001]
  • [Cites] Ann Pharmacother. 2001 Oct;35(10):1166-72 [11675839.001]
  • [Cites] J Am Geriatr Soc. 1997 Aug;45(8):945-8 [9256846.001]
  • [Cites] Arch Intern Med. 2000 Oct 9;160(18):2825-31 [11025793.001]
  • [Cites] Eur J Intern Med. 2003 Oct;14(6):372-376 [14769496.001]
  • [Cites] J Am Pharm Assoc (Wash). 2000 May-Jun;40(3):417-24 [10853543.001]
  • [Cites] Eur J Clin Pharmacol. 2004 May;60(3):217-20 [15069591.001]
  • [Cites] Ann Pharmacother. 2002 Nov;36(11):1675-81 [12398558.001]
  • [Cites] J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6):847-57 [12482007.001]
  • [Cites] CMAJ. 1997 Feb 1;156(3):385-91 [9033421.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Sep;1(1):38-43 [15555464.001]
  • [Cites] J Clin Epidemiol. 1992 Oct;45(10):1045-51 [1474400.001]
  • (PMID = 17111245.001).
  • [ISSN] 0928-1231
  • [Journal-full-title] Pharmacy world & science : PWS
  • [ISO-abbreviation] Pharm World Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Song M, Park JE, Park SG, Lee DH, Choi HK, Park BC, Ryu SE, Kim JH, Cho S: NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun; 2009 Apr 17;381(4):491-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since DUSP26 is involved in survival of anaplastic thyroid cancer (ATC) cells, NSC-87877 could be a therapeutic reagent for treating ATC.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233143.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / NSC-87877; 0 / Quinolines; EC 3.1.3.- / Mitogen-Activated Protein Kinase Phosphatases; EC 3.1.3.48 / DUSP26 protein, human; EC 3.1.3.48 / Dual-Specificity Phosphatases; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6
  •  go-up   go-down


89. Yano Y, Kamma H, Matsumoto H, Fujiwara M, Bando H, Hara H, Yashiro T, Ueno E, Ito K, Uchida K: Growth suppression of thyroid cancer cells by adenylcyclase activator. Oncol Rep; 2007 Aug;18(2):441-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth suppression of thyroid cancer cells by adenylcyclase activator.
  • Thyroid stimulating hormone (TSH) is known to increase intracytoplasmic cyclic adenosine monophosphate (cAMP) and to regulate the growth of normal follicular cells.
  • The aim of this study was to explore the role of the cAMP-mediated signaling pathway stimulated by TSH as a cell growth modulator in human thyroid cancer cells.
  • One papillary thyroid cancer cell line, K1 cells and two anaplastic thyroid cancer cell lines, TTA1 and TTA2 cells were treated with forskolin, which directly activates adenyl cyclase to raise the level of intracellular cAMP.
  • Forskolin suppressed thyroid cancer cell proliferations, especially in K1 cells, in a dose-dependent manner and induced growth arrest at the G0/G1 phase of the cell cycle.
  • In conclusion, we demonstrated that forskolin was involved in G1 arrest and MAPK activation in K1 thyroid cancer cells.
  • Our study suggests that the TSH signal mediated by cAMP acts as a negative regulator in thyroid cancer cells, unlike that in normal follicular cells.
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Hepatocyte Growth Factor / pharmacology. Humans. Insulin-Like Growth Factor I / pharmacology. MAP Kinase Signaling System / drug effects. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation / drug effects. Receptors, Thyrotropin / genetics. Receptors, Thyrotropin / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology. Time Factors

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611668.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Thyrotropin; 1F7A44V6OU / Colforsin; 67256-21-7 / Hepatocyte Growth Factor; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 4.6.1.1 / Adenylyl Cyclases
  •  go-up   go-down


90. Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, Zhang H, Qian X, Sebo TJ, Erickson LA, Lloyd RV: RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest; 2005 Sep;85(9):1065-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors.
  • We analyzed RASSF1A and NORE1A methylation and BRAF mutation in 89 thyroid tumors, 42 non-neoplastic thyroid tissues and three thyroid tumor cell lines using polymerase chain reaction (PCR), methylation-specific PCR, Western blotting and DNA sequencing in order to study thyroid tumor pathogenesis and progression.
  • RASSF1A promoter methylation was present in all three thyroid cell lines and in 27/78 (35%) of benign and malignant thyroid tumors.
  • We also examined for the first time NORE1A promoter region methylation in thyroid cell lines and primary tumors and showed that two of three thyroid cell lines were methylated in the NORE1A promoter region, while all primary thyroid tumors analyzed (n=51) were unmethylated.
  • BRAF mutation was present in 38% of papillary thyroid carcinomas (PTC), including 20% of PTC with a follicular variant pattern and 67% of the tall cell variant of PTC.
  • These results indicate that RASSF1A epigenetic changes are an early event in thyroid tumor pathogenesis and progression and that NORE1A methylation is uncommon in primary thyroid tumors.
  • BRAF mutation occurs later in thyroid tumor progression and is restricted mainly to PTC and anaplastic thyroid carcinoma.
  • [MeSH-major] DNA Methylation. Monomeric GTP-Binding Proteins / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980887.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RASSF1 protein, human; 0 / RASSF5 protein, human; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  •  go-up   go-down


91. Zhang P, Martin PD, Purcarea C, Vaishnav A, Brunzelle JS, Fernando R, Guy-Evans HI, Evans DR, Edwards BF: Dihydroorotase from the hyperthermophile Aquifex aeolicus is activated by stoichiometric association with aspartate transcarbamoylase and forms a one-pot reactor for pyrimidine biosynthesis. Biochemistry; 2009 Feb 03;48(4):766-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In prokaryotes, the first three enzymes in pyrimidine biosynthesis, carbamoyl phosphate synthetase (CPS), aspartate transcarbamoylase (ATC), and dihydroorotase (DHO), are commonly expressed separately and either function independently (Escherichia coli) or associate into multifunctional complexes (Aquifex aeolicus).
  • In mammals the enzymes are expressed as a single polypeptide chain (CAD) in the order CPS-DHO-ATC and associate into a hexamer.
  • This study presents the three-dimensional structure of the noncovalent hexamer of DHO and ATC from the hyperthermophile A. aeolicus at 2.3 A resolution.
  • In the crystal structure, six DHO and six ATC chains form a hollow dodecamer, in which the 12 active sites face an internal reaction chamber that is approximately 60 A in diameter and connected to the cytosol by narrow tunnels.

  • Hazardous Substances Data Bank. OROTIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Genet. 2000 Jan;16(1):9-11 [10637623.001]
  • [Cites] Proteins. 1999 Dec 1;37(4):729-42 [10651286.001]
  • [Cites] Methods Enzymol. 2001;331:248-70 [11265467.001]
  • [Cites] Biochemistry. 2001 Jun 19;40(24):6989-97 [11401542.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41 [11517324.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1451-6 [11567159.001]
  • [Cites] Reproduction. 2002 Jun;123(6):757-68 [12052230.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24490-8 [11959858.001]
  • [Cites] J Synchrotron Radiat. 2003 Jan 1;10(Pt 1):23-5 [12511787.001]
  • [Cites] Proteins. 2003;53 Suppl 6:491-6 [14579338.001]
  • [Cites] Curr Opin Struct Biol. 2003 Dec;13(6):665-73 [14675543.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52924-34 [14534296.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33035-8 [15096496.001]
  • [Cites] Nature. 1968 Jun 22;218(5147):1119-21 [5656633.001]
  • [Cites] Arch Biochem Biophys. 1969 Nov;134(2):352-65 [4311178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 May;72(5):1712-6 [168571.001]
  • [Cites] J Biol Chem. 1980 Dec 10;255(23):11372-80 [6108322.001]
  • [Cites] J Biol Chem. 1980 Dec 10;255(23):11381-95 [6108323.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6802-6 [2995985.001]
  • [Cites] Methods Enzymol. 1985;113:627-35 [3937019.001]
  • [Cites] J Mol Biol. 1985 Dec 20;186(4):715-24 [3912514.001]
  • [Cites] J Biol Chem. 1986 May 5;261(13):6073-83 [2871022.001]
  • [Cites] Science. 1988 Aug 5;241(4866):669-74 [3041592.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(1):46-50 [2643106.001]
  • [Cites] Trends Biochem Sci. 1990 Feb;15(2):53-9 [2186515.001]
  • [Cites] Science. 1992 Mar 20;255(5051):1544-50 [1549782.001]
  • [Cites] J Biol Chem. 1995 Jun 30;270(26):15620-7 [7797560.001]
  • [Cites] J Mol Graph. 1996 Feb;14(1):33-8, 27-8 [8744570.001]
  • [Cites] J Bacteriol. 1997 Jun;179(11):3470-81 [9171389.001]
  • [Cites] Eur J Biochem. 1997 Aug 1;247(3):1063-73 [9288932.001]
  • [Cites] Comp Biochem Physiol A Physiol. 1997 Nov;118(3):463-73 [9406429.001]
  • [Cites] Protein Sci. 1998 May;7(5):1083-91 [9605313.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1998 Jul 1;54(Pt 4):547-57 [9761849.001]
  • [Cites] Adv Microb Physiol. 1998;40:281-351 [9889981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1240-5 [9990008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5388-93 [10318893.001]
  • [Cites] Science. 1999 Jul 30;285(5428):751-3 [10427000.001]
  • [Cites] Curr Microbiol. 1999 Oct;39(4):175-9 [10486051.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32 [15572765.001]
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):53136-44 [15381710.001]
  • [Cites] Biochemistry. 2004 Dec 28;43(51):16285-92 [15610022.001]
  • [Cites] J Mol Biol. 2005 May 6;348(3):523-33 [15826651.001]
  • [Cites] J Mol Biol. 2005 May 6;348(3):535-47 [15826652.001]
  • [Cites] Biochemistry. 2005 May 3;44(17):6383-91 [15850372.001]
  • [Cites] Bioinformatics. 2005 Jun 15;21(12):2832-8 [15802286.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1668-88 [16200636.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1701-18 [16211538.001]
  • [Cites] Proteins. 2005 Dec 1;61(4):704-21 [16231289.001]
  • [Cites] BMC Bioinformatics. 2006;7:316 [16792811.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):108-17 [17164533.001]
  • [Cites] Biophys J. 2007 Mar 1;92(5):1792-805 [17172310.001]
  • [Cites] Proteins. 2007 Mar 1;66(4):824-37 [17154422.001]
  • [Cites] Science. 2007 Apr 13;316(5822):254-61 [17431175.001]
  • [Cites] Curr Opin Struct Biol. 2007 Jun;17(3):370-7 [17574831.001]
  • [Cites] J Mol Biol. 2007 Sep 21;372(3):774-97 [17681537.001]
  • [Cites] Science. 2008 Jun 13;320(5882):1428-9 [18556536.001]
  • (PMID = 19128030.001).
  • [ISSN] 1520-4995
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 3D6N
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060371; United States / NHLBI NIH HHS / HL / R01 HL057527; United States / NHLBI NIH HHS / HL / HL47399; United States / NHLBI NIH HHS / HL / HL57527; United States / NIGMS NIH HHS / GM / R01 GM047399; United States / NCI NIH HHS / CA / CA60321; United States / NIGMS NIH HHS / GM / GM60321; United States / NIGMS NIH HHS / GM / GM47399
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Multienzyme Complexes; 0 / Pyrimidines; 155-54-4 / 4,5-dihydroorotic acid; 61H4T033E5 / Orotic Acid; EC 2.1.3.2 / Aspartate Carbamoyltransferase; EC 3.5.2.3 / Dihydroorotase
  • [Other-IDs] NLM/ NIHMS529265; NLM/ PMC3863388
  •  go-up   go-down


92. Roche B, Larroumets G, Dejax C, Kwiatkowsi F, Desbiez F, Thieblot P, Tauveron I: Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC). Comparison with the literature. Ann Endocrinol (Paris); 2010 Feb;71(1):38-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC). Comparison with the literature.
  • OBJECTIVE: The aim of this study is to retrospectively describe the epidemiological and clinical features, therapeutic modalities, prognostic factors and survival figures in a population of patients with anaplastic thyroid carcinoma (ATC) observed in Auvergne, France.
  • MATERIAL AND METHODS: The analysis was conducted based on a computer database containing a regional register recorded by health professionals treating ATC.
  • RESULTS: Of the 1500 cancers observed over 16 years, 26 were identified as ATC.
  • The male/female ratio was 1/2.7 and the average age: 72.1; 76.9% of the cases had thyroid medical history, average tumor size at diagnosis was 7.35 cm with N1 in the course of illness in 61.5% of cases, M1 in 34.6% of cases.
  • [MeSH-major] Carcinoma / therapy. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19959159.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


93. Roswall P, Bu S, Rubin K, Landström M, Heldin NE: 2-methoxyestradiol induces apoptosis in cultured human anaplastic thyroid carcinoma cells. Thyroid; 2006 Feb;16(2):143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-methoxyestradiol induces apoptosis in cultured human anaplastic thyroid carcinoma cells.
  • Anaplastic thyroid carcinoma (ATC) is one of the most malignant tumors in humans, and currently there is no effective treatment.
  • In the present study we investigated the effect of an endogenous estrogen metabolite, 2-methoxyestradiol (2-ME), on the growth of human ATC cells.
  • 2-ME treatment had a strong growth inhibitory effect on five human ATC cell lines (HTh7, HTh 74, HTh83, C643, and SW1736), but showed no effect on one cell line (KAT-4).
  • Taken together, our data demonstrate an antiproliferative and apoptotic effect of 2-ME on ATC cells involving activation of MAPKs.
  • [MeSH-major] Apoptosis. Carcinoma / drug therapy. Carcinoma / metabolism. Estradiol / analogs & derivatives. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Caspase 3. Caspase 8. Caspases / metabolism. Cell Line, Tumor. DNA Fragmentation. Flow Cytometry. G1 Phase. Humans. In Situ Nick-End Labeling. MAP Kinase Signaling System. Models, Statistical. Osmosis. RNA, Messenger / metabolism. Ribonucleases / metabolism. Time Factors. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676399.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.1.- / Ribonucleases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases
  •  go-up   go-down


94. Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, Yu YA, Timiryasova T, Chen N, Shah JP, Szalay AA, Fong Y, Wong RJ: Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery; 2007 Dec;142(6):976-83; discussion 976-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus.
  • BACKGROUND: Anaplastic thyroid carcinoma (ATC) is a fatal disease resistant to all conventional treatments.
  • Infection of 6 ATC cell lines by GLV-1h68 was detected in vitro at 12, 24, and 36 hours.
  • CONCLUSION: A replication-competent vaccinia virus has significant infectious and oncolytic activity against a panel of human ATC.
  • These results encourage future in vivo and clinical studies for this novel agent to treat this fatal cancer.
  • [MeSH-major] Carcinoma / therapy. Oncolytic Virotherapy / methods. Thyroid Neoplasms / therapy. Vaccinia virus / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063085.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Galactosides; 0 / Indoles; 147336-22-9 / Green Fluorescent Proteins; EC 1.13.12.- / Luciferases; EC 3.2.1.23 / beta-Galactosidase; V595OG374W / 5-bromo-4-chloro-3-indolyl beta-galactoside
  •  go-up   go-down


95. Weijers G, Starke A, Haudum A, Thijssen JM, Rehage J, De Korte CL: Interactive vs. automatic ultrasound image segmentation methods for staging hepatic lipidosis. Ultrason Imaging; 2010 Jul;32(3):143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interactive vs. automatic ultrasound image segmentation methods for staging hepatic lipidosis.
  • The aim of this study was to test the hypothesis that automatic segmentation of vessels in ultrasound (US) images can produce similar or better results in grading fatty livers than interactive segmentation.
  • A study was performed in postpartum dairy cows (N=151), as an animal model of human fatty liver disease, to test this hypothesis.
  • Ultrasonic tissue characterization (UTC) parameters--Mean echo level, standard deviation (SD) of echo level, signal-to-noise ratio (SNR), residual attenuation coefficient (ResAtt) and axial and lateral speckle size--were derived using a computer-aided US (CAUS) protocol and software package.
  • Automatic-segmentation algorithms were implemented and it was investigated whether better results could be achieved than with the subjective and time-consuming interactive-segmentation procedure.
  • The automatic-segmentation algorithms were based on both fixed and adaptive thresholding techniques in combination with a 'speckle'-shaped moving-window exclusion technique.
  • This enabled us to study the effect of the applied postprocessing steps on single and multiple linear regressions ofthe various UTC parameters with TAG.
  • Improved correlations for all US parameters were found by using automatic-segmentation techniques.
  • Best speckle-size estimates and overall performance (R2 = 0.71, AUC = 0.94) were achieved by using an SNR-based adaptive automatic-segmentation method (used TAG threshold: 50 mg/g liver wet weight).
  • Automatic segmentation is thus feasible and profitable.
  • [MeSH-minor] Algorithms. Animals. Area Under Curve. Biopsy. Cattle. Disease Models, Animal. Female. Linear Models. ROC Curve. Sensitivity and Specificity. Software. Triglycerides / metabolism. Ultrasonography

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718244.001).
  • [ISSN] 0161-7346
  • [Journal-full-title] Ultrasonic imaging
  • [ISO-abbreviation] Ultrason Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Triglycerides
  •  go-up   go-down


96. Sakji S, Letord C, Pereira S, Dahamna B, Joubert M, Darmoni J: Drug information portal in Europe: information retrieval with multiple health terminologies. Stud Health Technol Inform; 2009;150:497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DIP has created specific functionalities related to drug and used specific drugs terminologies and classifications: the ATC classification, the CAS numbers, the French codes CIS, and CIP, as well as trade names and the International Nonproprietary Names of the drugs.

  • MedlinePlus Health Information. consumer health - Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19745361.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  •  go-up   go-down


97. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, Mandal M, Myers JN: Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther; 2005 Apr;4(4):632-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788.
  • Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human malignancies with a mean survival of only 6 months.
  • The poor prognosis of patients with ATC reflects the current lack of curative therapeutic options and the need for development of novel therapeutic strategies.
  • In this study, we report the results of a preclinical study of AEE788, a dual inhibitor of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, against ATC.
  • AEE788 was able to inhibit the proliferation and induce apoptosis of ATC cell lines in vitro.
  • ATC xenografts inhibited the growth of ATC xenografts by 44% and 69%, respectively, compared with the control group.
  • The microvessel density within the ATC xenografts was decreased by >80% in the mice treated with AEE788 alone and in combination with paclitaxel compared with the control group.
  • Considering the fact that curative options seldom exist for patients with ATC, concurrent inhibition of EGFR and VEGFR tyrosine kinases seems to be a valid and promising anticancer strategy for these patients.
  • [MeSH-major] Carcinoma / drug therapy. Purines / pharmacology. Thyroid Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827337.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097007A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AEE 788; 0 / Antineoplastic Agents; 0 / Purines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


98. Ahlstrom U: Work domain analysis for air traffic controller weather displays. J Safety Res; 2005;36(2):159-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Adverse weather conditions have a major impact on National Airspace System (NAS) operations.
  • They create safety hazards for pilots, constrain the usable airspace for air traffic control (ATC), and reduce the overall capacity of the NAS.
  • A system-wide dissemination of weather information to controllers could theoretically improve safety and efficiency.
  • Furthermore, no previous research has empirically evaluated optimal presentation designs for ATC weather displays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878775.001).
  • [ISSN] 0022-4375
  • [Journal-full-title] Journal of safety research
  • [ISO-abbreviation] J Safety Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Molander L, Gerstrand M, Rudén C: WikiPharma - a freely available, easily accessible, interactive and comprehensive database for environmental effect data for pharmaceuticals. Regul Toxicol Pharmacol; 2009 Dec;55(3):367-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The database currently contains basic information, i.e. substance name, ATC code(s) and pharmaceutical group(s), for 831 APIs representing 35 different drug classes.
  • [MeSH-minor] Environmental Exposure / adverse effects. Humans. Sweden. Water Pollutants, Chemical / adverse effects

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19720105.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Water Pollutants, Chemical
  •  go-up   go-down


100. Burnett S, Blakemore SJ: Functional connectivity during a social emotion task in adolescents and in adults. Eur J Neurosci; 2009 Mar;29(6):1294-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this fMRI study we investigated functional connectivity between components of the mentalising system during a social emotion task, using psychophysiological interaction (PPI) analysis.
  • In both adults and adolescents, an anterior rostral region of medial prefrontal cortex (arMPFC) involved in mentalising showed greater connectivity with the posterior superior temporal sulcus (pSTS) bordering on the temporo-parietal junction (TPJ) and with anterior temporal cortex (ATC) during social than during basic emotion.
  • This result provides novel evidence that components of the mentalising system interact functionally during a social emotion task.
  • The adolescent group showed stronger connectivity between arMPFC and pSTS/TPJ during social relative to basic emotion than did the adult group, suggestive of developmental changes in functional integration within the mentalising system.

  • MedlinePlus Health Information. consumer health - Family Issues.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • SciCrunch. NeuroSynth: Data: Activation Foci .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Neurosci. 1999 Oct;2(10):861-3 [10491603.001]
  • [Cites] J Comp Neurol. 1999 Aug 2;410(3):343-67 [10404405.001]
  • [Cites] Cogn Behav Neurol. 2005 Mar;18(1):68-78 [15761278.001]
  • [Cites] Neuropsychologia. 2005;43(10):1391-9 [15936784.001]
  • [Cites] Nat Rev Neurosci. 2006 Apr;7(4):268-77 [16552413.001]
  • [Cites] Neuroimage. 2006 Apr 15;30(3):1059-68 [16337813.001]
  • [Cites] Behav Brain Res. 2007 Jul 19;181(1):12-22 [17467816.001]
  • [Cites] Neuroimage. 2007 Jul 15;36(4):1065-73 [17513132.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13507-12 [17679691.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):4028-32 [18322013.001]
  • [Cites] Nat Rev Neurosci. 2008 Apr;9(4):267-77 [18354399.001]
  • [Cites] Hum Brain Mapp. 2008 Jun;29(6):696-710 [17598163.001]
  • [Cites] Neuroimage. 2008 Jul 15;41(4):1345-51 [18495496.001]
  • [Cites] J Cogn Neurosci. 2008 Dec;20(12):2125-36 [18457502.001]
  • [Cites] Nat Rev Neurosci. 2008 Dec;9(12):947-57 [19002191.001]
  • [Cites] Hum Brain Mapp. 2009 Jan;30(1):24-37 [17979124.001]
  • [Cites] Cereb Cortex. 2009 Mar;19(3):640-57 [18653667.001]
  • [Cites] Soc Cogn Affect Neurosci. 2007 Jun;2(2):130-9 [17710201.001]
  • [Cites] J Cogn Neurosci. 2009 Sep;21(9):1736-50 [18823226.001]
  • [Cites] Soc Cogn Affect Neurosci. 2006 Sep;1(2):107-21 [18985123.001]
  • [Cites] Soc Cogn Affect Neurosci. 2007 Sep;2(3):217-26 [18985143.001]
  • [Cites] Psychol Rep. 2002 Dec;91(3 Pt 1):743-57 [12530718.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2003 Mar 29;358(1431):459-73 [12689373.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(11):2475-80 [12814380.001]
  • [Cites] Neuroimage. 2003 Aug;19(4):1835-42 [12948738.001]
  • [Cites] Brain Res Cogn Brain Res. 2003 Dec;18(1):48-57 [14659496.001]
  • [Cites] Neuroreport. 2004 Feb 9;15(2):219-23 [15076740.001]
  • [Cites] Brain Res. 1979 Mar 16;163(2):195-205 [427544.001]
  • [Cites] Neurosci Lett. 1982 Dec 13;33(3):247-52 [7162689.001]
  • [Cites] Arch Gen Psychiatry. 1994 Jun;51(6):477-84 [8192550.001]
  • [Cites] Neuroreport. 1995 Sep 11;6(13):1741-6 [8541472.001]
  • [Cites] Exp Brain Res. 1997 Jul;115(3):430-44 [9262198.001]
  • [Cites] J Comp Neurol. 1997 Oct 20;387(2):167-78 [9336221.001]
  • [Cites] Neuroimage. 1997 Oct;6(3):218-29 [9344826.001]
  • [Cites] Percept Mot Skills. 2004 Oct;99(2):371-91 [15560325.001]
  • (PMID = 19302165.001).
  • [ISSN] 1460-9568
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC2695858
  •  go-up   go-down






Advertisement